CARLSBAD, CA, USA I November 3, 2014 I Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of ISIS-GSK5Rx as a development candidate. ISIS-GSK5Rx is an antisense drug designed to treat an undisclosed ocular disease.
“ISIS-GSK5Rx is the second drug in our collaboration with GSK to enter development to treat an ocular disease. This drug utilizes the unique properties of antisense to selectively reduce the production of a target known to be involved in various ocular diseases. We look forward to advancing this program and sharing more information on the target and disease,” said B. Lynne Parshall, chief operating officer at Isis. “Our collaboration with GSK has been very productive and has resulted in a number of novel antisense drugs in our pipeline to treat a diverse range of diseases.”
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 33 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH. Isis has numerous drugs in Phase 3 development in severe and rare and cardiovascular disease. These include a novel triglyceride lowering drug, ISIS-APOCIIIRx, for patients with familial chylomicronemia syndrome; ISIS-TTRRx, which Isis is developing with GSK to treat patients with the polyneuropathy form of TTR amyloidosis; and, ISIS-SMNRx, which Isis is developing with Biogen Idec to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE: GlaxoSmithKline
Post Views: 220
CARLSBAD, CA, USA I November 3, 2014 I Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of ISIS-GSK5Rx as a development candidate. ISIS-GSK5Rx is an antisense drug designed to treat an undisclosed ocular disease.
“ISIS-GSK5Rx is the second drug in our collaboration with GSK to enter development to treat an ocular disease. This drug utilizes the unique properties of antisense to selectively reduce the production of a target known to be involved in various ocular diseases. We look forward to advancing this program and sharing more information on the target and disease,” said B. Lynne Parshall, chief operating officer at Isis. “Our collaboration with GSK has been very productive and has resulted in a number of novel antisense drugs in our pipeline to treat a diverse range of diseases.”
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 33 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ partner, Genzyme, is commercializing Isis’ lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH. Isis has numerous drugs in Phase 3 development in severe and rare and cardiovascular disease. These include a novel triglyceride lowering drug, ISIS-APOCIIIRx, for patients with familial chylomicronemia syndrome; ISIS-TTRRx, which Isis is developing with GSK to treat patients with the polyneuropathy form of TTR amyloidosis; and, ISIS-SMNRx, which Isis is developing with Biogen Idec to treat infants and children with spinal muscular atrophy, a severe and rare neuromuscular disease. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
SOURCE: GlaxoSmithKline
Post Views: 220
